Galectin Therapeutics (GALT)
Add to Watchlists Create an AlertGALT Key Stats
| Income Statement | |
| Revenue TTM | 0.00 |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -0.7196 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -9.675M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 68.32M |
| Enterprise Value | 58.94M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 128.19 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -1.754M |
| Return on Equity | -453.5% |
GALT News
- Galectin Therapeutics to Hold Conference Call to Provide Update Following Compan... 9:16 AM
- GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financia... 2:18 AM
- GALECTIN THERAPEUTICS INC Financials May 17
- Nasdaq stocks posting largest volume increases May 15
- Galectin Therapeutics to Hold Conference Call to Provide Update Following Compan... May 15
- GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financia... May 15
- Galectin (GALT) Posts Q1 Loss of 22c/Share Street Insider May 10
- Galectin Therapeutics Reports First Quarter 2013 Financial Results PR Newswire May 10
- GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financia... May 10
- GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 10
GALT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Galectin Therapeutics is up 102.9% over the last year vs S&P 500 Total Return up 28.33%, Acura Pharmaceuticals down 18.40%, and AVANIR Pharmaceuticals up 22.12%.
GALT Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these GALT related companies
Pro Ratings for GALT
Pro Report PDF for GALT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download GALT Pro Report PDF
Pro Strategies Featuring GALT
Did Galectin Therapeutics make it into our Pro Portfolio Strategies?
GALT Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Other GALT Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GALT | 4.22 | +0.04 | +0.96% | 68.32M |
